Scrip
US panel backs Amgen's denosumab for osteoporosis treatment but not prevention
14 August 2009
Sue Sutter
Please Login to read the full article.
14 August 2009
Sue Sutter
The US
FDA's outside experts have unanimously endorsed approval of
Amgen's first-in-class RANK ligand inhibitor Prolia (denosumab) for treatment of postmenopausal osteoporosis (PMO). However, panellists voted 12 to three against a prevention indication, saying they wanted more long-term...
Please Login to read the full article.
RELATED CONTENT
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
